Skip to main content
SpringerLink
Log in

The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Medullary thyroid carcinoma (MTC) occurs as a sporadic form or, less frequently, as an autosomal dominant inherited familial disorder. Germline mutations in the RET proto-oncogene in exons 10, 11, 13, 14, 15, and 16 are found in most of the familial cases (nearly 95%). Somatic mutations in sporadic MTC are detected in 23–69% of patients. The most frequent somatic mutation is located in exon 16 at codon 918, and only a small percentage of mutations are found in exons 10, 11, 13, and 15. We have searched for somatic mutations in Czech MTC patients using direct sequencing. We report here two new somatic missense mutations in exon 16 of the RET proto-oncogene associated with the sporadic MTC detected in two Czech men. A homozygous mutation at codon 922 TCC(Ser)→CCC(Pro) as a result of loss of heterozygosity was revealed in the first patient. In the second one a heterozygous mutation at codon 930 ACG(Thr)→ATG(Met) was found.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

MEN :

Multiple endocrine neoplasia

MTC :

Medullary thyroid carcinoma

PCR :

Polymerase chain reaction

References

  1. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851–856

    Google Scholar 

  2. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241

    Google Scholar 

  3. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460

    CAS  PubMed  Google Scholar 

  4. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238:343–346

    CAS  PubMed  Google Scholar 

  5. Ishizaka Y, Itoh F, Tahira T, Ikeda I, Sugimura T, Tucker J, Fertitta A, Carrano AV, Nagao M (1989) Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4:1519–1521

    CAS  PubMed  Google Scholar 

  6. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ (1995) Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12:209–212

    CAS  PubMed  Google Scholar 

  7. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G (1995) Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088–3090

    CAS  PubMed  Google Scholar 

  8. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BAJ (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509–513

    CAS  PubMed  Google Scholar 

  9. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M (1999) Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 90:1231–1237

    CAS  PubMed  Google Scholar 

  10. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249–257

    Google Scholar 

  11. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619–1622

    CAS  PubMed  Google Scholar 

  12. Bugalho MJ, Coelho I, Sobrinho LG (2000) Somatic trinucleotide change encompassing codons 882 and 883 of the RET proto-oncogene in a patient with sporadic medullary thyroid carcinoma. Eur J Endocrinol 142:573–575

    CAS  PubMed  Google Scholar 

  13. Kalinin V, Frilling A (1998) 27-bp Deletion in the RET proto-oncogene as a somatic mutation associated with medullary thyroid carcinoma. J Mol Med 76:365–367

    CAS  PubMed  Google Scholar 

  14. Alemi M, Lucas SD, Sallstrom JF, Akerstrom G, Wilander E (1996) A novel deletion in the RET proto-oncogene found in sporadic medullary thyroid carcinoma. Anticancer Res 16:2619–2622

    CAS  PubMed  Google Scholar 

  15. Alemi M, Lucas SD, Sallstrom JF, Bergholm U, Akerstrom G, Wilander E (1997) A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma. Oncogene 14:2041–2045

    Article  CAS  PubMed  Google Scholar 

  16. Kalinin VN, Amosenko FA, Shabanov MA, Lubchenko LN, Hosch SB, Garkavtseva RF, Izbicki JR (2001) Three novel mutations in the RET proto-oncogene. J Mol Med 79:609–612

    Article  CAS  PubMed  Google Scholar 

  17. Kitamura Y, Scavarda N, Wells Jr SA, Jackson CE, Goodfellow PJ (1995) Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum Mol Genet 5:1987–1988

    Google Scholar 

  18. Uchino S, Noguchi S, Adachi M, Sato M, Yamashita H, Watanabe S, Murakami T, Toda M, Murakami N, Yamashita H (1998) Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res 89:411–418

    CAS  PubMed  Google Scholar 

  19. Miyauchi A, Egawa S, Futami H, Kuma K, Obara T, Yamaguchi K (1997) A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation. Jpn J Cancer Res 88:527–531

    CAS  PubMed  Google Scholar 

  20. Fox EA (1994) Preparation of DNA from fixed, paraffin-embedded tissue. Curr Protocols Human Genet A3I:1–5

    Google Scholar 

  21. Hanks SK, Quinn AM, Hunter T (1998) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42–52

    Google Scholar 

  22. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91:1579–1583

    CAS  PubMed  Google Scholar 

  23. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267:381–383

    CAS  PubMed  Google Scholar 

  24. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375–376

    CAS  PubMed  Google Scholar 

  25. Songyang Z, Carraway KL 3rd, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–539

    Article  CAS  PubMed  Google Scholar 

  26. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekete C, Munnich A (1995) Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 4:1381–1386

    Google Scholar 

  27. Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ, Lips CJ (2002) Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 87:393–397

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the grant IGA MH CR NC/6650-3.

Author information

Authors and Affiliations

  1. Department of Molecular Endocrinology, Institute of Endocrinology, Narodni 8, 11694 Prague 1, Czech Republic

    S. Jindrichova & B. Bendlova

  2. Institute of Pathological Anatomy, 2nd Medical Faculty, Charles University, Prague, Czech Republic

    R. Kodet & L. Krskova

  3. Department of Nuclear Medicine, 2nd Medical Faculty, Charles University, Prague, Czech Republic

    P. Vlcek

Authors
  1. S. Jindrichova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Kodet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Krskova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Vlcek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Bendlova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Jindrichova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jindrichova, S., Kodet, R., Krskova, L. et al. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 81, 819–823 (2003). https://doi.org/10.1007/s00109-003-0501-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-003-0501-4

Keywords

Search

Navigation